NEWS

Elkedonia CEO Delphine Charvin Named Best Emerging BioTech CEO 2026 by EU Business News

Elkedonia's co-founder and CEO, Delphine Charvin, PhD, has been recognized as Best Emerging BioTech CEO 2026 at the European CEO of the Year Awards, hosted by EU Business News. Elkedonia was also named Most Innovative Non-Addictive Depression Therapeutics Developer 2026.

Elkedonia, a preclinical-stage biotech company developing a first-in-class treatment for major depressive disorder (MDD), today announces that its co-founder and CEO, Delphine Charvin, PhD, has been named Best Emerging BioTech CEO 2026 at the European CEO of the Year Awards, hosted by EU Business News. Elkedonia was also recognized as Most Innovative Non-Addictive Depression Therapeutics Developer 2026.

The European CEO of the Year Awards honor leaders who demonstrate strategic vision and a strong impact on their organizations and industries.

This recognition adds to a year of milestones for Elkedonia. In September 2026, Delphine Charvin and co-founder Mélanie Rouillier received the EY Entrepreneur of the Year Award in the Scale-up category for the Grand Est region, and Elkedonia was named a laureate of the 2026 i-Lab innovation competition, operated by Bpifrance under France 2030.

This recognition reflects the mission at the heart of Elkedonia's program: bringing a new kind of treatment to people living with major depressive disorder, a condition affecting 332 million people worldwide, a third of whom do not respond to current treatments. Elkedonia is developing a first-in-class neuroplastogen targeting ELK1, a novel non-synaptic protein, designed to act rapidly from the first dose without hallucination, dissociation, or risk of addiction.

"I am deeply honored, and this recognition belongs to the entire Elkedonia team. Together with our Scientific Advisory Board, our investors and our partners, we are building a new kind of treatment for people living with depression: one that acts fast, without the burdens of today's rapid-acting options. We are just getting started."
- Delphine Charvin, PhD, co-founder and CEO of Elkedonia

Read more on EU Business News: https://www.eubusinessnews.com/winners/elkedonia/

About Elkedonia

Elkedonia is developing a first-in-class neuroplastogen for major depressive disorder, a condition affecting 332 million people worldwide, around one third of whom do not respond adequately to current treatments. Its approach targets ELK1, a novel non-synaptic protein whose therapeutic relevance is supported by patient data and validated in preclinical models. Elkedonia is the first spin-off of the Argobio startup studio and builds on research from Sorbonne Université, CNRS and INSERM. Since May 2025, the company has raised more than €11 million from a syndicate of leading European life sciences investors. Elkedonia was named a laureate of the 2026 i-Lab innovation competition.